Skip to content
  • Sunday, 26 July 2026
  • 2:49 am
  • Follow Us
Lab DB
  • Home
  • About Us
    • About Us
    • Affiliate Disclosure
    • Cookie Policy
    • Disclaimer
    • Privacy Policy
    • DMCA
    • Terms of Service
  • Contact Us
  • FAQ
  • Home
  • Novo Nordisk’s triple agonist delivers up to 19.7% average weight loss in Phase 2 trial
Laboratory Automation & Robotics

Novo Nordisk’s triple agonist delivers up to 19.7% average weight loss in Phase 2 trial

Lana Keisha Mar 25, 2026 0

Novo Nordisk’s investigational triple agonist, UBT251, has demonstrated a mean weight loss of 19.7% after 24 weeks in a Phase…

Read More
Laboratory Automation & Robotics

Novo Nordisk Sues Hims for GLP-1 Patent Infringement

Lana Keisha Mar 20, 2026 0

In a significant escalation of the ongoing battle over the burgeoning GLP-1 weight-loss drug market, pharmaceutical giant Novo Nordisk has…

Read More
Laboratory Automation & Robotics

Novo Nordisk’s new weight loss treatment inferior to Lilly’s tirzepatide

Lana Keisha Mar 18, 2026 0

Novo Nordisk, a global leader in diabetes and obesity care, announced on Monday that its investigational weight loss treatment, CagriSema,…

Read More
Laboratory Automation & Robotics

Novo Nordisk’s triple agonist delivers up to 19.7% average weight loss in Phase 2 trial

Lana Keisha Mar 18, 2026 0

Novo Nordisk, a global leader in diabetes and obesity care, announced a significant advancement in its weight management pipeline with…

Read More

Posts pagination

1 … 3 4
GLP-1 Receptor Agonists and the Emerging Question of Anticancer EffectsPharmSci 360 2026 heads to New Orleans this OctoberTrumpRx.gov: A Federal Portal’s Ambitions and the Intensifying Scrutiny of Direct-to-Consumer Drug SalesAnthropic’s Claude API Deepens Integration with Python Ecosystem, Offering Robust Toolkit for Advanced AI Development
MEDVi Under Scrutiny: AI-Powered Telehealth Startup Faces FDA Warnings, Deceptive Marketing Allegations, and Multiple Lawsuits Despite Meteoric GrowthLLMOps in 2026: The 10 Tools Every Team Must HaveJapan’s FY26 NHI Drug Price Revision: Deeper Dive into Mechanisms and Market ImpactThe Most Favored Nation (MFN) Policy’s Unforeseen Ripple Effect: European Pharmaceutical Launches and Withdrawals Plummet
Remepy, a startup that pairs drugs with AI-driven apps, clears a Phase IIa test in Parkinson’sKing’s College London Researchers Identify Potential Breakthrough Alzheimer’s Treatment Through Repurposed Spinal Cord Injury Drug KCL-286Living Plastics That Self-Destruct: Scientists Engineer Microbe-Embedded Polymers for Complete and Rapid DecompositionSanofi Discontinues Amlitelimab Development in Atopic Dermatitis, Citing Lack of Meaningful Differentiation
YOU MAY HAVE MISSED
Laboratory Automation & Robotics
Remepy, a startup that pairs drugs with AI-driven apps, clears a Phase IIa test in Parkinson’s
Lana Keisha Jul 25, 2026
Neuroscience & Brain Research
King’s College London Researchers Identify Potential Breakthrough Alzheimer’s Treatment Through Repurposed Spinal Cord Injury Drug KCL-286
Rifan Muazin Jul 25, 2026
Advanced Materials Science
Living Plastics That Self-Destruct: Scientists Engineer Microbe-Embedded Polymers for Complete and Rapid Decomposition
Nila Kartika Wati Jul 25, 2026
Pharmaceutical R&D
Sanofi Discontinues Amlitelimab Development in Atopic Dermatitis, Citing Lack of Meaningful Differentiation
Teuku Ryan Jul 25, 2026

Copyright © 2025 | Powered by WordPress | News Gadgets by ThemeArile

  • Home
  • About Us
    • About Us
    • Affiliate Disclosure
    • Cookie Policy
    • Disclaimer
    • Privacy Policy
    • DMCA
    • Terms of Service
  • Contact Us
  • FAQ